Items where authors include "Denton, C.P."

Article

Lescoat, A., Bellando-Randone, S., Campochiaro, C. et al. (9 more authors) (2023) Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine. The Lancet Rheumatology, 5 (11). e683-e694. ISSN 2665-9913

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 62 (9). pp. 3133-3138. ISSN 1462-0324

Spiera, R. orcid.org/0000-0003-2911-6800, Kuwana, M. orcid.org/0000-0001-8352-6136, Khanna, D. orcid.org/0000-0003-1412-4453 et al. (28 more authors) (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 75 (9). pp. 1608-1618. ISSN 2326-5191

Lepri, G., Hughes, M., Allanore, Y. et al. (8 more authors) (2023) The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution. The Lancet Rheumatology, 5 (7). e422-e425. ISSN 2665-9913

Denton, C.P. orcid.org/0000-0003-3975-8938, De Lorenzis, E., Roblin, E. et al. (27 more authors) (2023) Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (1). rkad022. ISSN 2514-1775

Denton, C.P. orcid.org/0000-0003-3975-8938, del Galdo, F. orcid.org/0000-0002-8528-2283, Khanna, D. et al. (12 more authors) (2023) Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 62 (1). pp. 234-242. ISSN 1462-0324

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology. ISSN 1462-0324

Kakkar, V., Assassi, S., Allanore, Y. et al. (4 more authors) (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6). pp. 357-364. ISSN 1040-8711

Hughes, M., Allanore, Y., Baron, M. et al. (13 more authors) (2022) Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology, 4 (11). e795-e803. ISSN 2665-9913

Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983

Bageghni, S.A., Hemmings, K.E., Yuldasheva, N.Y. et al. (11 more authors) (2019) Fibroblast-specific deletion of IL-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight, 4 (17). ISSN 2379-3708

Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967

Proceedings Paper

Del Galdo, F. orcid.org/0000-0002-8528-2283, Lescoat, A., Conaghan, P.G. et al. (24 more authors) (2023) OP0234 2023 Update Of Eular Recommendations For The Treatment Of Systemic Sclerosis. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 154-155.

Bruni, C., Tofani, L., Fretheim, H. et al. (55 more authors) (2023) OP0238 Immunosuppression With Targeted Dmards Reduces Morbidity And Mortality In Pre-Capillary Pulmonary Hypertension Associated With Systemic Sclerosis: A Eustar Analysis. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 157-159.

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.